Wahl

Wolmark

Susan G. Komen selected Geoffrey M. Wahl, PhD and Norman Wolmark, MD, FACS, FRCSC recipients of this year’s Brinker Awards which will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS) Dec. 6-10.

Dr. Wahl will receive the Brinker Award for Scientific Distinction in Basic Science. He is the Daniel and Martina Lewis Chair and professor at the Salk Institute for Biological Studies Gene Expression Laboratory in La Jolla, Calif.

Dr. Wahl is being recognized for his contributions to the field of cancer genetics, including the mechanisms of drug resistance and genome stability according to a release from Komen. His research and pioneering techniques have led to discoveries across numerous disciplines. Dr. Wahl’s commitment to the understanding of the development of mammary cells led to discoveries in breast cancer research and treatment. It also enabled a better understanding of the signaling changes influencing the onset and progression of breast cancer cells while identifying opportunities for targeted drug therapies according to Komen.

Dr. Wolmark will receive the Brinker Award for Scientific Distinction in Clinical Research. He is the professor of surgery at the University of Pittsburgh UPMC Hillman Cancer Center, chairman of the NSABP Foundation Inc., and an NRG Oncology Group Chair and Contact Principal Investigator.

Komen is recognizing Wolmark for his, “for his innovation and significant contributions to patient care. He was instrumental in establishing breast-conserving surgery as the standard of care for invasive and non-invasive breast cancer, eliminating the need for radical mastectomy, offering options and improving the quality of life for breast cancer patients. Over the last four decades, Dr. Wolmark has led numerous clinical trials, including two of the largest chemoprevention clinical trials leading to FDA approval of the use of tamoxifen and raloxifene for breast cancer prevention in high-risk patients.”

Dr. Wahl’s presentation, “Guardian at the Gates: Genome Stability, Cell State, Plasticity, and Breast Cancer,” will be 12:30 p.m. Thursday, Dec. 8. Dr. Wolmark’s talk will be, “The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer: PAST AS PROLOGUE,” Friday, Dec. 9 at 11:30 a.m.

Visit the following link for an abbreviated schedule.

The 45^th annual San Antonio Breast Cancer Symposium will be Dec. 6-10 at the Henry B. Gonzalez Convention Center.